Daewon Pharmaceutical (003220.KS) Earnings Analysis

Daewon Pharmaceutical (003220.KS) has no confirmed upcoming earnings date. It has beaten estimates in 0/3 recent quarters (0%). Trailing P/E -37.78.

Last updated 2026-07-23 · Source: FMP fundamentals + earnings calendar (company filings); consensus from sell-side analyst grades

When does 003220.KS next report earnings?

No confirmed upcoming earnings date is currently scheduled for 003220.KS. This page updates as the calendar is published.

003220.KS earnings history — beats and misses

Quarter (report date)EPS actualEPS est.SurpriseResult
2026-05-15113.01 KRWn/an/an/a
2026-02-03633.65 KRWn/an/an/a
2025-08-14-138.00023 KRWn/an/an/a
2025-02-07-49.4605 KRW253.44 KRW-119.5%Miss
2024-11-14316.63 KRW356.49 KRW-11.2%Miss
2024-08-14-36 KRW568.73 KRW-106.3%Miss

Beat rate: 0/3 (0%) over reported quarters with consensus data.

003220.KS valuation and analyst view

Trailing P/E-37.78
Trailing EPS-204.35207 KRW
Price / book0.63
Dividend yield3.24%
Market cap162.25B

Limited or no published sell-side analyst coverage for this symbol.

Related research pages

Frequently asked questions

When is Daewon Pharmaceutical (003220.KS)'s next earnings date?

No confirmed upcoming earnings date is currently scheduled for 003220.KS. This page updates as the calendar is published.

Did 003220.KS beat earnings last quarter?

Consensus estimate data was not available for 003220.KS's 2026-05-15 report.

What is 003220.KS's earnings track record?

Over the last 3 reported quarters with consensus data, 003220.KS beat estimates 0 times (0%).

What is 003220.KS's current P/E ratio and EPS?

003220.KS trades at a trailing P/E of -37.78 on trailing EPS of -204.35207390472635 KRW.

What do analysts rate 003220.KS?

003220.KS has limited or no published sell-side analyst coverage in our dataset, so no consensus rating is shown. Fundamentals and earnings history above are sourced from company filings via FMP.